These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 22646267)

  • 1. A histopathologic pattern of centrilobular hepatocyte injury suggests 6-mercaptopurine-induced hepatotoxicity in patients with inflammatory bowel disease.
    Masia R; Pratt DS; Misdraji J
    Arch Pathol Lab Med; 2012 Jun; 136(6):618-22. PubMed ID: 22646267
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Nodular regenerative hyperplasia as a complication of thiopurine treatment in a patient with inflammatory bowel disease].
    Cohen-Ezra O; Avni Y; Morgenstern S; Ben-Ari Z
    Harefuah; 2012 Dec; 151(12):675-8, 721. PubMed ID: 23330258
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence, risk factors and clinical course of thiopurine-induced liver injury in patients with inflammatory bowel disease.
    Bastida G; Nos P; Aguas M; Beltrán B; Rubín A; Dasí F; Ponce J
    Aliment Pharmacol Ther; 2005 Nov; 22(9):775-82. PubMed ID: 16225485
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of non-cirrhotic portal hypertension associated with thiopurine therapy in inflammatory bowel disease.
    Calabrese E; Hanauer SB
    J Crohns Colitis; 2011 Feb; 5(1):48-53. PubMed ID: 21272804
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histopathology of liver biopsies from a thiopurine-naïve inflammatory bowel disease cohort: prevalence of nodular regenerative hyperplasia.
    De Boer NK; Tuynman H; Bloemena E; Westerga J; Van Der Peet DL; Mulder CJ; Cuesta MA; Meuwissen SG; Van Nieuwkerk CM; Van Bodegraven AA
    Scand J Gastroenterol; 2008; 43(5):604-8. PubMed ID: 18415755
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatotoxicity associated with 6-methyl mercaptopurine formation during azathioprine and 6-mercaptopurine therapy does not occur on the short-term during 6-thioguanine therapy in IBD treatment.
    van Asseldonk DP; Seinen ML; de Boer NK; van Bodegraven AA; Mulder CJ
    J Crohns Colitis; 2012 Feb; 6(1):95-101. PubMed ID: 22261533
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thiopurine metabolite monitoring in paediatric inflammatory bowel disease.
    Ooi CY; Bohane TD; Lee D; Naidoo D; Day AS
    Aliment Pharmacol Ther; 2007 Apr; 25(8):941-7. PubMed ID: 17402998
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adverse events of thiopurine immunomodulators in patients with inflammatory bowel disease.
    López-Martín C; Chaparro M; Espinosa L; Bejerano A; Maté J; Gisbert JP
    Gastroenterol Hepatol; 2011; 34(6):385-92. PubMed ID: 21616565
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intrauterine exposure and pharmacology of conventional thiopurine therapy in pregnant patients with inflammatory bowel disease.
    Jharap B; de Boer NK; Stokkers P; Hommes DW; Oldenburg B; Dijkstra G; van der Woude CJ; de Jong DJ; Mulder CJ; van Elburg RM; van Bodegraven AA;
    Gut; 2014 Mar; 63(3):451-7. PubMed ID: 23424097
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Thiopurine-induced hyperammonaemic encephalopathy in a patient with Crohn's disease].
    Laish I; Pomeranz I; Kitay-Cohen Y; Konikof F
    Harefuah; 2012 Dec; 151(12):692-5, 720. PubMed ID: 23330262
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mercaptopurine treatment should be considered in azathioprine intolerant patients with inflammatory bowel disease.
    Hindorf U; Johansson M; Eriksson A; Kvifors E; Almer SH
    Aliment Pharmacol Ther; 2009 Mar; 29(6):654-61. PubMed ID: 19183142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-life study of safety of thiopurine-allopurinol combination therapy in inflammatory bowel disease: myelotoxicity and hepatotoxicity rarely affect maintenance treatment.
    Kreijne JE; de Veer RC; de Boer NK; Dijkstra G; West R; Moorsel SAW; de Jong DJ; van der Woude CJ; de Vries AC;
    Aliment Pharmacol Ther; 2019 Aug; 50(4):407-415. PubMed ID: 31359480
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liver steatosis is a risk factor for hepatotoxicity in patients with inflammatory bowel disease under immunosuppressive treatment.
    Schröder T; Schmidt KJ; Olsen V; Möller S; Mackenroth T; Sina C; Lehnert H; Fellermann K; Büning J
    Eur J Gastroenterol Hepatol; 2015 Jun; 27(6):698-704. PubMed ID: 25923946
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early hepatic nodular hyperplasia and submicroscopic fibrosis associated with 6-thioguanine therapy in inflammatory bowel disease.
    Geller SA; Dubinsky MC; Poordad FF; Vasiliauskas EA; Cohen AH; Abreu MT; Tran T; Martin P; Vierling JM; Targan SR
    Am J Surg Pathol; 2004 Sep; 28(9):1204-11. PubMed ID: 15316320
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Toxicity of 6-thioguanine: no hepatotoxicity in a series of IBD patients treated with long-term, low dose 6-thioguanine. Some evidence for dose or metabolite level dependent effects?
    Gilissen LP; Derijks LJ; Driessen A; Bos LP; Hooymans PM; Stockbrügger RW; Engels LG
    Dig Liver Dis; 2007 Feb; 39(2):156-9. PubMed ID: 17188950
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Should thiopurine methyltransferase genotypes and phenotypes be measured before thiopurine therapy in patients with inflammatory bowel disease?
    Fangbin Z; Xiang G; Minhu C; Liang D; Feng X; Min H; Pinjin H
    Ther Drug Monit; 2012 Dec; 34(6):695-701. PubMed ID: 23149442
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatotoxicity of 6-mercaptopurine (6-MP) and Azathioprine (AZA) in adult IBD patients.
    Shaye OA; Yadegari M; Abreu MT; Poordad F; Simon K; Martin P; Papadakis KA; Ippoliti A; Vasiliauskas E; Tran TT
    Am J Gastroenterol; 2007 Nov; 102(11):2488-94. PubMed ID: 17764490
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 6-Thioguanine-related hepatotoxicity in patients with inflammatory bowel disease: dose or level dependent?
    Derijks LJ; Gilissen LP; de Boer NK; Mulder CJ
    J Hepatol; 2006 Apr; 44(4):821-2. PubMed ID: 16487623
    [No Abstract]   [Full Text] [Related]  

  • 19. Allopurinol enhanced thiopurine treatment for inflammatory bowel disease: safety considerations and guidelines for use.
    Min MX; Weinberg DI; McCabe RP
    J Clin Pharm Ther; 2014 Apr; 39(2):107-11. PubMed ID: 24438369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early prediction of thiopurine-induced hepatotoxicity in inflammatory bowel disease.
    Wong DR; Coenen MJ; Derijks LJ; Vermeulen SH; van Marrewijk CJ; Klungel OH; Scheffer H; Franke B; Guchelaar HJ; de Jong DJ; Engels LG; Verbeek AL; Hooymans PM;
    Aliment Pharmacol Ther; 2017 Feb; 45(3):391-402. PubMed ID: 27943397
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.